Hao-Wei Teng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hao-Wei Teng has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Chueh-Chuan Yen
Division of Medical Oncology, Center for Immuno‐Oncology, Department of Oncology Taipei Veterans General Hospital Taipei Taiwan
3 shared publications - Chun-Yu Liu
Comprehensive Breast Health Center, Taipei Veterans General Hospital, Taipei, Taiwan
3 shared publications - Chia-Jen Liu
Division of Transfusion Medicine, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
2 shared publications - Jen-Kou Lin
Division of Colon & Rectal Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei 11217, Taiwan
2 shared publications - Jeng-Kai Jiang
Taipei Veterans General Hospital
2 shared publications - Ming-Huang Chen
Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan
2 shared publications
Latest Publications
- Open Access
- 15 June 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Circulating N6-methyladenosine RNA as a diagnostic and a stage-associated prognostic biomarker in colorectal cancer
Extracellular vesicle (EV)-based liquid biopsy is increasingly recognized as a promising strategy for cancer diagnosis and prognosis, as EVs carry abundant
- 15 June 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessCirculating N6-methyladenosine RNA as a diagnostic and a stage-associated prognostic biomarker in colorectal cancer
Extracellular vesicle (EV)-based liquid biopsy is increasingly recognized as a promising strategy for cancer diagnosis and prognosis, as EVs carry abundant
- Open Access
- 22 May 2019
- Published by Springer Nature in EJNMMI Research
- Vol. 9 (1) , 1-13
A phase 0 study of the pharmacokinetics, biodistribution, and dosimetry of 188Re-liposome in patients with metastatic tumors
Liposomes are drug nano-carriers that are capable of targeting therapeutics to tumor sites because of enhanced permeability retention (EPR). In several preclinical studies with various tumor-bearing mice models, 188Re-liposome that has been developed by the Institute of Nuclear Energy Research (INER) demonstrates favorable in vivo tumor targeting, biodistribution, pharmacokinetics, and dosimetry. It inhibits the growth of tumors, increased survival, demonstrates good synergistic combination, and was safe to use. This study conducts a phase 0 low-radioactivity clinical trial of nano-targeted radiotherapeutics 188Re-liposome to evaluate the effectiveness with which it targets tumors and the pharmacokinetics, biodistribution, dosimetry, and its safety in use. Twelve patients with metastatic cancers are studied in this trial. Serial whole-body scans and SPECT/CT are taken at 1, 4, 8, 24, 48, and 72 h after intravenous injection of 111 MBq of 188Re-liposome. The effectiveness with which tumors are targeted, the pharmacokinetics, biodistribution, dosimetry, and safety are evaluated using the VelocityAI and OLINDA/EXM software. Blood samples are collected at different time points for a pharmacokinetics study and a safety evaluation that involves monitoring changes in liver, renal, and hematological functions. The T½z for 188Re-liposome in blood and plasma are 36.73 ± 14.00 h and 52.02 ± 45.21 h, respectively. The doses of radiation that are absorbed to vital organs such as the liver, spleen, lung, kidney, and bone marrow are 0.92 ± 0.35, 1.38 ± 1.81, 0.58 ± 0.28, 0.32 ± 0.09, and 0.06 ± 0.01 mGy/MBq, respectively, which is far less than the reference maximum tolerance dose after injection of 188Re-liposome. 188Re-liposome is absorbed by metastatic tumor lesions and the normal reticuloendothelial (RES) system. Certain patients exhibit a therapeutic response. This phase 0 exploratory IND study shows that nanocarrier 188Re-liposome achieves favorable tumor accumulation and tumor to normal organ uptake ratios for a subset of cancer patients. The clinical pharmacokinetic, biodistribution, and dosimetry results justify a further dose-escalating phase 1 clinical trial. Taiwan FDA MA1101G0 (Jan 31, 2012).
- 22 May 2019
- Published by Springer Nature in EJNMMI Research
- Vol. 9 (1) , 1-13
Open AccessA phase 0 study of the pharmacokinetics, biodistribution, and dosimetry of 188Re-liposome in patients with metastatic tumors
Liposomes are drug nano-carriers that are capable of targeting therapeutics to tumor sites because of enhanced permeability retention (EPR). In several preclinical studies with various tumor-bearing mice models, 188Re-liposome that has been developed by the Institute of Nuclear Energy Research (INER) demonstrates favorable in vivo tumor targeting, biodistribution, pharmacokinetics, and dosimetry. It inhibits the growth of tumors, increased survival, demonstrates good synergistic combination, and was safe to use. This study conducts a phase 0 low-radioactivity clinical trial of nano-targeted radiotherapeutics 188Re-liposome to evaluate the effectiveness with which it targets tumors and the pharmacokinetics, biodistribution, dosimetry, and its safety in use. Twelve patients with metastatic cancers are studied in this trial. Serial whole-body scans and SPECT/CT are taken at 1, 4, 8, 24, 48, and 72 h after intravenous injection of 111 MBq of 188Re-liposome. The effectiveness with which tumors are targeted, the pharmacokinetics, biodistribution, dosimetry, and safety are evaluated using the VelocityAI and OLINDA/EXM software. Blood samples are collected at different time points for a pharmacokinetics study and a safety evaluation that involves monitoring changes in liver, renal, and hematological functions. The T½z for 188Re-liposome in blood and plasma are 36.73 ± 14.00 h and 52.02 ± 45.21 h, respectively. The doses of radiation that are absorbed to vital organs such as the liver, spleen, lung, kidney, and bone marrow are 0.92 ± 0.35, 1.38 ± 1.81, 0.58 ± 0.28, 0.32 ± 0.09, and 0.06 ± 0.01 mGy/MBq, respectively, which is far less than the reference maximum tolerance dose after injection of 188Re-liposome. 188Re-liposome is absorbed by metastatic tumor lesions and the normal reticuloendothelial (RES) system. Certain patients exhibit a therapeutic response. This phase 0 exploratory IND study shows that nanocarrier 188Re-liposome achieves favorable tumor accumulation and tumor to normal organ uptake ratios for a subset of cancer patients. The clinical pharmacokinetic, biodistribution, and dosimetry results justify a further dose-escalating phase 1 clinical trial. Taiwan FDA MA1101G0 (Jan 31, 2012).
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e15119
Outcome disparities in elder patients with colorectal cancer receiving definitive surgery: A nationwide population-based study in Taiwan.
E15119 Background: There are increasing numbers of elderly patients with colorectal cancer (CRC). With the advance of cancer treatment in recent years, more elderly CRC patients receive curative surgery and multidisciplinary cancer treatment. The purpose of this study is to identify the risk factors of mortality and to improve survival of these patients. Methods: We recruited newly diagnosed CRC patients between 2005 and 2012 from Taiwan's nationwide health insurance database. Patients without definitive surgery for CRC were excluded. CRC patients aged < 65 years (non-elderly) were served as a reference group. The study cohort was followed until the end of 2013. Univariate and multivariate Cox proportional hazards models were applied to find the predictors of death among our study cohort. Results: During the 9-year study period, 10,818 (30.6%) died among 35,298 elderly CRC patients receiving definitive surgery, with a median follow-up period of 3.0 years. The median overall survival (OS) of the elderly patients was improved 1.4% per year (95% confidence interval [CI] 0.5–2.4%). Multivariate analysis showed that adjusted hazard ratios (HRs) for OS were 1.00, 1.23, 1.56, 2.15 in the patients aged 65–70, 70–75, 75–80, and ≥ 80 compared to those aged < 65, respectively. The older patients had a higher probability of having ≥ 2 underlying comorbidities (71.4% vs. 31.4%) and without postoperative treatment (42.1% vs. 28.8%), which might be associated with the increase of mortality risk. Conclusions: This largest cohort study demonstrated an increasing risk of mortality in elderly CRC patients, especially those with ≥ 2 underlying comorbidities and those without postoperative treatment. [Table: see text]
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e15119
Outcome disparities in elder patients with colorectal cancer receiving definitive surgery: A nationwide population-based study in Taiwan.
E15119 Background: There are increasing numbers of elderly patients with colorectal cancer (CRC). With the advance of cancer treatment in recent years, more elderly CRC patients receive curative surgery and multidisciplinary cancer treatment. The purpose of this study is to identify the risk factors of mortality and to improve survival of these patients. Methods: We recruited newly diagnosed CRC patients between 2005 and 2012 from Taiwan's nationwide health insurance database. Patients without definitive surgery for CRC were excluded. CRC patients aged < 65 years (non-elderly) were served as a reference group. The study cohort was followed until the end of 2013. Univariate and multivariate Cox proportional hazards models were applied to find the predictors of death among our study cohort. Results: During the 9-year study period, 10,818 (30.6%) died among 35,298 elderly CRC patients receiving definitive surgery, with a median follow-up period of 3.0 years. The median overall survival (OS) of the elderly patients was improved 1.4% per year (95% confidence interval [CI] 0.5–2.4%). Multivariate analysis showed that adjusted hazard ratios (HRs) for OS were 1.00, 1.23, 1.56, 2.15 in the patients aged 65–70, 70–75, 75–80, and ≥ 80 compared to those aged < 65, respectively. The older patients had a higher probability of having ≥ 2 underlying comorbidities (71.4% vs. 31.4%) and without postoperative treatment (42.1% vs. 28.8%), which might be associated with the increase of mortality risk. Conclusions: This largest cohort study demonstrated an increasing risk of mortality in elderly CRC patients, especially those with ≥ 2 underlying comorbidities and those without postoperative treatment. [Table: see text]
- Open Access
- 11 August 2016
- Published by Springer Nature in SpringerPlus
- Vol. 5 (1) , 1318
Adjuvant FOLFOX treatment for stage III colon cancer: how many cycles are enough?
- 11 August 2016
- Published by Springer Nature in SpringerPlus
- Vol. 5 (1) , 1318
Open AccessAdjuvant FOLFOX treatment for stage III colon cancer: how many cycles are enough?
- 1 October 2011
- Published by Update Medical Publishing in Hepatogastroenterology
- Vol. 58 (110-111) , 1495-501
The Efficacy of Chemotherapy in Patients with High-Grade Metastatic Colon Cancer
This study was undertaken to assess the prognostic role of histological grade in colon cancer and the efficacy of either oxaliplatin or irinotecan after incorporation into an infusional regimen of 5-fluorouracil and leucovorin in patients with high-grade metastatic colon cancer. Data from 2409 consecutive and eligible patients with colon cancer from a single institute was used to assess the impact of histological grade on survival and the efficacy of the two doublet regimens on patients with metastatic colon cancer relative to histological grade. High histological grade has unfavorable outcome for patients with stage III (p=0.021) or stage IV (p=0.003) colon cancer but not for those with stage I (p=0.703) or stage II (p=0.767) colon cancer. Progression free survival and overall survival in patients with high-grade metastatic colon cancer were not improved by the addition of irinotecan or oxaliplatin to the infusional 5-fluorouracil + leucovorin regimen. Histological grade is a prognostic factor in stage III/IV colon cancer but not in stage I/II. Oxaliplatin and irinotecan may not enhance the efficacy of infusional 5-fluorouracil + leucovorin in the treatment of high-grade metastatic colon cancer.
- 1 October 2011
- Published by Update Medical Publishing in Hepatogastroenterology
- Vol. 58 (110-111) , 1495-501
The Efficacy of Chemotherapy in Patients with High-Grade Metastatic Colon Cancer
This study was undertaken to assess the prognostic role of histological grade in colon cancer and the efficacy of either oxaliplatin or irinotecan after incorporation into an infusional regimen of 5-fluorouracil and leucovorin in patients with high-grade metastatic colon cancer. Data from 2409 consecutive and eligible patients with colon cancer from a single institute was used to assess the impact of histological grade on survival and the efficacy of the two doublet regimens on patients with metastatic colon cancer relative to histological grade. High histological grade has unfavorable outcome for patients with stage III (p=0.021) or stage IV (p=0.003) colon cancer but not for those with stage I (p=0.703) or stage II (p=0.767) colon cancer. Progression free survival and overall survival in patients with high-grade metastatic colon cancer were not improved by the addition of irinotecan or oxaliplatin to the infusional 5-fluorouracil + leucovorin regimen. Histological grade is a prognostic factor in stage III/IV colon cancer but not in stage I/II. Oxaliplatin and irinotecan may not enhance the efficacy of infusional 5-fluorouracil + leucovorin in the treatment of high-grade metastatic colon cancer.
- 13 April 2010
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 137 (2) , 211-220
Diabetes mellitus negatively impacts survival of patients with colon cancer, particularly in stage II disease
This retrospective study aimed to determine the effects of diabetes on overall survival (OS) and cancer-specific survival (CSS) in patients with newly diagnosed colon cancers, with particular focus on the impact of diabetes on survival at each stage of colon cancer. From January 1999 to January 2008, 2762 consecutive patients diagnosed with colon cancer in Taipei Veterans General Hospital were enrolled. The general characteristics as well as presence of diabetes prior to colon cancer diagnosis were identified. Cox proportional hazard analyses were used for prognostic factors determination; and survival was analyzed using the Kaplan–Meier method with log-rank test. A total of 469 patients (17%) had diabetes at diagnosis of colon cancer. Patients with diabetes had baseline characteristics comparable to those without diabetes with the exception that the patients with diabetes were older (>65 years). Diabetes significantly and negatively impacted OS and CSS in multivariate analyses. After adjusting for possible confounding factors, the prognostic impact of diabetes on OS and CSS was particularly significant in patients with stage II colon cancer. Diabetes is a poor prognostic factor in patients with newly diagnosed colon cancer, and it may directly impact the tumor behavior of stage II disease. Further study is required to elucidate the underlying pathophysiologic mechanisms.
- 13 April 2010
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 137 (2) , 211-220
Diabetes mellitus negatively impacts survival of patients with colon cancer, particularly in stage II disease
This retrospective study aimed to determine the effects of diabetes on overall survival (OS) and cancer-specific survival (CSS) in patients with newly diagnosed colon cancers, with particular focus on the impact of diabetes on survival at each stage of colon cancer. From January 1999 to January 2008, 2762 consecutive patients diagnosed with colon cancer in Taipei Veterans General Hospital were enrolled. The general characteristics as well as presence of diabetes prior to colon cancer diagnosis were identified. Cox proportional hazard analyses were used for prognostic factors determination; and survival was analyzed using the Kaplan–Meier method with log-rank test. A total of 469 patients (17%) had diabetes at diagnosis of colon cancer. Patients with diabetes had baseline characteristics comparable to those without diabetes with the exception that the patients with diabetes were older (>65 years). Diabetes significantly and negatively impacted OS and CSS in multivariate analyses. After adjusting for possible confounding factors, the prognostic impact of diabetes on OS and CSS was particularly significant in patients with stage II colon cancer. Diabetes is a poor prognostic factor in patients with newly diagnosed colon cancer, and it may directly impact the tumor behavior of stage II disease. Further study is required to elucidate the underlying pathophysiologic mechanisms.
- 1 January 2008
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 49 (10) , 2018-2021
Sustained remission and long-term survival of secondary central nervous system involvement by aggressive B-cell lymphoma after combination treatment of systemic high-dose chemotherapy and intrathecal rituximab
- 1 January 2008
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 49 (10) , 2018-2021
Sustained remission and long-term survival of secondary central nervous system involvement by aggressive B-cell lymphoma after combination treatment of systemic high-dose chemotherapy and intrathecal rituximab